Leukemia & Lymphoma最新文献_第2页

Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. 对于IDH2突变型难治性/复发性急性髓细胞性白血病老年患者，依那西尼与常规治疗的成本效益对比。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-19 DOI: 10.1080/10428194.2024.2426073

Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica M Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, George Goshua, Jan Philipp Bewersdorf, Amer M Zeidan

{"title":"Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.","authors":"Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica M Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, George Goshua, Jan Philipp Bewersdorf, Amer M Zeidan","doi":"10.1080/10428194.2024.2426073","DOIUrl":"10.1080/10428194.2024.2426073","url":null,"abstract":"In the randomized phase III IDHENTIFY trial, the IDH2 inhibitor enasidenib (ENA) showed improvement in event-free but not overall survival compared with conventional care regimens (CCR) among patients with relapsed/refractory (R/R), IDH2-mutant AML. We constructed a partitioned survival model to evaluate the cost-effectiveness of enasidenib for the treatment of older patients with R/R, and IDH2-mutant AML. In the base-case scenario, ENA exhibited an incremental effectiveness of 0.234quality-adjusted life-years (QALYs) compared to CCR, and an incremental cost of $126,800, leading to an incremental cost-effectiveness ratio of $540,300/QALY(95% CI: $197,800-$4,777,000/QALY). In probabilistic sensitivity analysis, CCR was favored in 99.8% of simulations. The cost of ENA would need to be decreased by 72% to be cost-effective at a willingness-to-pay threshold of $150,000/QALY. Our findings suggest that ENA is unlikely to be a cost-effective treatment for older patients with IDH2-mutant R/R AML under current pricing.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"488-496"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. 阿扎胞苷和 venetoclax 联合或不联合培伐地司他治疗新诊断的急性髓性白血病患者。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1080/10428194.2024.2431878

Nicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, Kamel Laribi, Christian Recher, Jaroslaw Czyz, Bogdan Ochrem, Lionel Ades, Maria Pilar Gallego-Hernanz, Mael Heiblig, Ernesta Audisio, Ewa Zarzycka, Shuli Li, Nicholas Ferenc, Tammie Yeh, Douglas V Faller, Farhad Sedarati, Cristina Papayannidis

{"title":"Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.","authors":"Nicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, Kamel Laribi, Christian Recher, Jaroslaw Czyz, Bogdan Ochrem, Lionel Ades, Maria Pilar Gallego-Hernanz, Mael Heiblig, Ernesta Audisio, Ewa Zarzycka, Shuli Li, Nicholas Ferenc, Tammie Yeh, Douglas V Faller, Farhad Sedarati, Cristina Papayannidis","doi":"10.1080/10428194.2024.2431878","DOIUrl":"10.1080/10428194.2024.2431878","url":null,"abstract":"This phase 2 study investigated pevonedistat + azacitidine + venetoclax (n = 83) versus azacitidine + venetoclax (n = 81) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. The study was stopped early following negative results from PANTHER, which evaluated pevonedistat in higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast AML. Outcomes were analyzed up to the datacut. For pevonedistat + azacitidine + venetoclax versus azacitidine + venetoclax, the median follow-up was 8.44 versus 7.95 months; the complete remission (CR) rate was 45% versus 49%; composite CR (CCR; CR+CR with incomplete blood count recovery) was 77% versus 72%. There were no differences in event-free survival (primary endpoint; hazard ratio [HR]: 0.99; 95% confidence interval [CI]: 0.61-1.60; p = 0.477) or overall survival (HR: 1.42; 95% CI: 0.82-2.49; p = 0.896). In exploratory analyses in IDH-mutated AML, CCR rates were higher with pevonedistat + azacitidine + venetoclax versus azacitidine + venetoclax. Safety was similar between treatment arms. Efficacy/safety with azacitidine + venetoclax was consistent with the phase 3 VIALE-A study.Trial registration: NCT04266795.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"458-468"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When and how to transplant in myelofibrosis - recent trends. 骨髓纤维化患者何时以及如何进行移植--最新趋势。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI: 10.1080/10428194.2024.2422835

Naman Sharma, Giuseppe G Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani, Alessandro M Vannucchi, Hassan B Alkhateeb, Ayalew Tefferi, Vincent T Ho

{"title":"When and how to transplant in myelofibrosis - recent trends.","authors":"Naman Sharma, Giuseppe G Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani, Alessandro M Vannucchi, Hassan B Alkhateeb, Ayalew Tefferi, Vincent T Ho","doi":"10.1080/10428194.2024.2422835","DOIUrl":"10.1080/10428194.2024.2422835","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (AHSCT) is currently the only treatment modality that is capable of curing myelofibrosis (MF). Although outcomes of AHSCT have improved vastly in recent years owing to advancements in HLA typing, conditioning regimens, and supportive care, it remains a procedure with a considerable risk in MF patients due to conditioning regimen related toxicity, higher rates of graft failure, infections, and graft versus host disease (GVHD). Recent progress in the treatment and prevention of GVHD with post-transplant cyclophosphamide has also rendered transplantation from alternative donors feasible and safer, thus improving access to patients without HLA-identical donors. Accordingly, all patients with intermediate or high-risk MF today should be referred for potential transplant evaluation to consider the pros and cons of an early versus a delayed transplant strategy. Individual risk assessment in MF is best facilitated by contemporary prognostic models that incorporate both clinical and genetic risk factors. The current review highlights new information regarding risk stratification in MF, anchored by practical algorithms that facilitate patient selection for specific treatment actions, including AHSCT.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"359-377"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes. 布利纳单抗治疗急性淋巴细胞白血病在现实世界的设置：临床小插曲。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-29 DOI: 10.1080/10428194.2024.2426052

Shilpa Paul, Elias Jabbour, E Dan Nichols, Nicholas J Short, Hagop Kantarjian

{"title":"Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.","authors":"Shilpa Paul, Elias Jabbour, E Dan Nichols, Nicholas J Short, Hagop Kantarjian","doi":"10.1080/10428194.2024.2426052","DOIUrl":"10.1080/10428194.2024.2426052","url":null,"abstract":"Blinatumomab, a CD19/CD3 bispecific T-cell engager; inotuzumab ozogamicin (INO), a CD22 antibody drug conjugate; and chimeric-antigen receptor (CAR) T-cell constructs are novel immune-therapeutic options for treatment of acute lymphoblastic leukemia (ALL). The use of blinatumomab has recently expanded to multiple B-ALL treatment settings. Despite the efficacy of blinatumomab, its use can be challenging in the real-world because of limited experience with its administration and management of toxicities. Optimal use and sequencing of blinatumomab is critical to improve outcomes, reduce undesired toxicities, and decrease discontinuation rates related to such toxicities. Herein, we discuss strategies to address the unique adverse effects of blinatumomab and ways to optimize its administration and integration into the treatment backbone of B-ALL. We outline our approach to combining and sequencing blinatumomab with other immunotherapies, such as INO and CD19 CAR T-cells, and provide recommendations for the management of toxicities and dose-optimization of blinatumomab therapy in clinical practice.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"389-399"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms. SRSF2/TET2共突变髓系肿瘤的分子格局和临床结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-29 DOI: 10.1080/10428194.2024.2432581

Samuel G Cockey, Hailing Zhang, Mohammed Hussaini, Ling Zhang, Lynn Moscinski, Ethan Yang, Julie Li, Le Wang, Jinming Song

{"title":"Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.","authors":"Samuel G Cockey, Hailing Zhang, Mohammed Hussaini, Ling Zhang, Lynn Moscinski, Ethan Yang, Julie Li, Le Wang, Jinming Song","doi":"10.1080/10428194.2024.2432581","DOIUrl":"10.1080/10428194.2024.2432581","url":null,"abstract":"The mutations in SRSF2 and TET2 genes are frequently present in various myeloid neoplasms. The potential impact of SRSF2/TET2 co-mutations on patient survival is incompletely understood. We identified 412 patients with SRSF2/TET2 co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as ASXL1, RUNX1, and KRAS with this co-mutation and their potential impact on patients' prognosis. We found that ASXL1, RUNX1, and KRAS can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"469-478"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges of treating mantle cell lymphoma in older adults. 老年人套细胞淋巴瘤治疗的挑战。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/10428194.2024.2431563

Javier Muñoz, Mazie Tsang, Yucai Wang, Tycel Phillips

引用次数: 0

Follow-up in patients with lymphoma: a call for an evidence-based approach. 淋巴瘤患者的随访：呼吁采取循证方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1080/10428194.2024.2426053

Marc Sorigue

引用次数: 0

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. 在IMerge三期研究中，对于不符合使用促红细胞生成药物条件或复发/难治且输血负担较重的低风险骨髓增生异常综合征患者，依美司他能持续改善患者报告的疲劳症状。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI: 10.1080/10428194.2024.2426057

Mikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, Rami S Komrokji, Pierre Fenaux, Michael R Savona, Yazan F Madanat, David Valcárcel-Ferreiras, Esther Natalie Oliva, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Amer M Zeidan, Uwe Platzbecker

引用次数: 0

CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia. CDKN2A/B缺失作为儿童B细胞前体急性淋巴细胞白血病异基因造血干细胞移植的独立负面预后因素

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-01 DOI: 10.1080/10428194.2024.2434177

Anna Paisiou, Christina OIkonomopoulou, Dimitris Pavlidis, Mirella Ampatzidou, Anna Komitopoulou, Eleni-Dikaia Ioannidou, Aikaterini Kaisari, Georgia Avgeriou, Nikolaos Katzilakis, Eleni Dana, Marianna Tzanoudaki, Michalis Kastamoulas, Georgia Stavroulaki, Eugenia Papakonstantinou, Emmanouil Hatzipantelis, Athanasios Tragiannidis, Dimitrios Doganis, Sophia Polychronopoulou, Stefanos Ioannis Papadhimitriou, Evgenios Goussetis

引用次数: 0

Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management. SAPS 3用于预测需要ICU管理的血液恶性肿瘤患者住院死亡率的验证

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-02 DOI: 10.1080/10428194.2024.2423251

Sebastián Gil-Tamayo, Cándida Díaz-Brochero, Julio Solano, Óscar Contreras, Laura Arenas, Sandra García, Óscar M Muñoz-Velandia

{"title":"Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management.","authors":"Sebastián Gil-Tamayo, Cándida Díaz-Brochero, Julio Solano, Óscar Contreras, Laura Arenas, Sandra García, Óscar M Muñoz-Velandia","doi":"10.1080/10428194.2024.2423251","DOIUrl":"10.1080/10428194.2024.2423251","url":null,"abstract":"Prognostic systems predicting death risk may vary for patients with haematological malignancies needing ICU care. This study externally validated SAPS 3 using a retrospective cohort of adults with these conditions in the ICU. The score was calculated at admission using the general and South America-adjusted formulas. Mortality discrimination was assessed via AUC-ROC, and calibration by Hosmer-Lemeshow goodness-of-fit and graphical analysis with a calibration belt. The analysis included 273 admissions, with 119 deaths. Discriminative capacity was low (AUC-ROC 0.56, CI 95% 0.49-0.63). There was a poor correlation between expected and observed events across all risk deciles (Hosmer-Lemeshow 10.45, p = 0.0635). Similar results were found with the South America-adjusted formula. SAPS 3 does not effectively discriminate between survivors and non-survivors, underestimating risk in low-risk groups and overestimating it in high-risk groups. Mortality risk estimation in this scenario should rely on clinical judgment.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"451-457"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0